Tech Company Financing Transactions

Neuraltus Pharmaceuticals Funding Round

On 3/26/2009, Neuraltus Pharmaceuticals raised $17 million in Series A financing from Adams Harkness Ventures, Latterell Venture Partners and VantagePoint Capital Partners.

Transaction Overview

Announced On
3/26/2009
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2479 E. Bayshore Rd. 220
Palo Alto, CA 94303
USA
Email Address
Overview
Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing innovative small molecule therapeutics for the treatment of neurodegenerative disorders.
Profile
Neuraltus Pharmaceuticals LinkedIn Company Profile
Social Media
Neuraltus Pharmaceuticals Company Twitter Account
Company News
Neuraltus Pharmaceuticals News
Facebook
Neuraltus Pharmaceuticals on Facebook
YouTube
Neuraltus Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
John Whelan
  John Whelan LinkedIn Profile  John Whelan Twitter Account  John Whelan News  John Whelan on Facebook
Chief Medical Officer
Gil Block
  Gil Block LinkedIn Profile  Gil Block Twitter Account  Gil Block News  Gil Block on Facebook
Chief Scientific Officer
Michael McGrath
  Michael McGrath LinkedIn Profile  Michael McGrath Twitter Account  Michael McGrath News  Michael McGrath on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/26/2009: Lifefactory venture capital transaction
Next: 3/26/2009: Thumbplay venture capital transaction

 

Share this article

 


News on VC Transactions

We report on tech company VC transactions. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary